Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death

International Journal of Cancer

Volumn 132, Issue 10, 2013, Pages 2248-2257

  Conradt, Laura ^a   Henrich, Annika ^a   Wirth, Matthias ^a   Reichert, Maximilian ^b   Lesina, Marina ^a   Algül, Hana ^a   Schmid, Roland M ^a   Krämer, Oliver H ^c   Saur, Dieter ^a   Schneider, Günter ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

DNA repair; Mdm2; Nbs1; p53; pancreatic cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CASPASE; ETOPOSIDE; GYRASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NUTLIN 1; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; PXN 822; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CELL CYCLE; CELL CYCLE M PHASE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG POTENTIATION; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; HYDROPHOBICITY; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DNA DAMAGE; DOXORUBICIN; DRUG SYNERGISM; ETOPOSIDE; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INDOLES; MICE; PANCREATIC NEOPLASMS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; PYRROLIDINONES; TOPOISOMERASE II INHIBITORS;

EID: 84874942708     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27916     Document Type: Article

References (43)

1. Manfredi JJ,. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 2010; 24: 1580-9.
2. Vousden KH, Prives C,. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-31.
3. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445: 656-60.
4. Martins CP, Brown-Swigart L, Evan GI,. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006; 127: 1323-34.
5. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445: 661-5.
6. Olivier M, Hollstein M, Hainaut P,. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010; 2: a001008.
7. Cheok CF, Verma CS, Baselga J, et al. Translating p53 into the clinic. Nat Rev Clin Oncol 2011; 8: 25-37.
8. Essmann F, Schulze-Osthoff K,. Translational approaches targeting the p53 pathway for anti-cancer therapy. Br J Pharmacol 2012; 165: 328-44.
9. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-8.
10. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006; 103: 1888-93.
11. Shangary S, Qin D, McEachern D, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008; 105: 3933-8.
12. Hidalgo M,. Pancreatic cancer. N Engl J Med 2010; 362: 1605-17.
13. Ebert M, Yokoyama M, Kobrin M, et al. Increased mdm2 expression and immunoreactivity in human pancreatic ductal adenocarcinoma. Int J Oncol 1994; 5: 1279-84.
14. Sui X, Shin S, Zhang R, et al. Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells. Oncogene 2009; 28: 709-20.
15. Azmi AS, Aboukameel A, Banerjee S, et al. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur J Cancer 2010; 46: 1122-31.
16. Schneider G, Henrich A, Greiner G, et al. Cross talk between stimulated NF-κB and the tumor suppressor p53. Oncogene 2010; 29: 2795-806.
17. Conradt L, Godl K, Schaab C, et al. Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma. Neoplasia 2011; 13: 1026-34.
18. Reichert M, Saur D, Hamacher R, et al. Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. Cancer Res 2007; 67: 4149-56.
19. Wirth M, Fritsche P, Stojanovic N, et al. A simple and cost-effective method to transfect small interfering RNAs into pancreatic cancer cell lines using polyethylenimine. Pancreas 2011; 40: 144-50.
20. Brandl M, Seidler B, Haller F, et al. IKK(α) controls canonical TGF(ss)-SMAD signaling to regulate genes expressing SNAIL and SLUG during EMT in panc1 cells. J Cell Sci 2010; 123: 4231-9.
21. Labisso WL, Wirth M, Stojanovic N, et al. MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors. Cell Cycle 2012; 11: 1593-602.
22. Sanjabi S, Williams KJ, Saccani S, et al. A c-Rel subdomain responsible for enhanced DNA-binding affinity and selective gene activation. Genes Dev 2005; 19: 2138-51.
23. Chou TC,. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-81.
24. Schneider G, Krämer OH,. NFκB/p53 crosstalk-a promising new therapeutic target. Biochim Biophys Acta 2011; 1815: 90-103.
25. Azmi AS, Banerjee S, Ali S, et al. Network modeling of MDM2 inhibitor-oxaliplatin combination reveals biological synergy in wt-p53 solid tumors. Oncotarget 2011; 2: 378-92.
26. Arlt A, Gehrz A, Muerkoster S, et al. Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003; 22: 3243-51.
27. Ivashkevich A, Redon CE, Nakamura AJ, et al. Use of the γ-H2AX assay to monitor DNA damage and repair in translational cancer research. Cancer Lett 2012; 327: 123-33.
28. Alt JR, Bouska A, Fernandez MR, et al. Mdm2 binds to Nbs1 at sites of DNA damage and regulates double strand break repair. J Biol Chem 2005; 280: 18771-81.
29. Bouska A, Eischen CM,. Mdm2 affects genome stability independent of p53. Cancer Res 2009; 69: 1697-701.
30. Bouska A, Lushnikova T, Plaza S, et al. Mdm2 promotes genetic instability and transformation independent of p53. Mol Cell Biol 2008; 28: 4862-74.
31. Blagosklonny MV,. How cancer could be cured by 2015. Cell Cycle 2005; 4: 269-78.
32. Heisig P,. Type II topoisomerases-inhibitors, repair mechanisms and mutations. Mutagenesis 2009; 24: 465-9.
33. Lamarche BJ, Orazio NI, Weitzman MD,. The MRN complex in double-strand break repair and telomere maintenance. FEBS Lett 2010; 584: 3682-95.
34. Lee JH, Paull TT,. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 2005; 308: 551-4.
35. Paull TT, Lee JH,. The Mre11/Rad50/Nbs1 complex and its role as a DNA double-strand break sensor for ATM. Cell Cycle 2005; 4: 737-40.
36. Uziel T, Lerenthal Y, Moyal L, et al. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J 2003; 22: 5612-21.
37. Bouska A, Eischen CM,. Murine double minute 2: p53-independent roads lead to genome instability or death. Trends Biochem Sci 2009; 34: 279-86.
38. Brandl A, Wagner T, Uhlig KM, et al. Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress. J Mol Cell Biol 2012; 4: 284-93.
39. Valentine JM, Kumar S, Moumen A,. A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation. BMC Cancer 2011; 11: 79.
40. Verma R, Rigatti MJ, Belinsky GS, et al. DNA damage response to the Mdm2 inhibitor nutlin-3. Biochem Pharmacol 2010; 79: 565-74.
41. Rigatti MJ, Verma R, Belinsky GS, et al. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells. Mol Carcinog 2012; 51: 363-78.
42. Roos WP, Kaina B,. DNA damage-induced apoptosis: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett, in press.
43. Galluzzi L, Vitale I, Abrams JM, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19: 107-20.